Werewolf Therapeutics (HOWL) Leerink’s Global Healthcare Conference 2025 summary

Key insights on cytokine therapy and innovation

• Emphasis on learning from past failures in cytokine therapy, focusing on improved tolerability, targeted delivery, and demonstrable monotherapy activity as critical success factors.

• Highlighted the importance of achieving durable responses, especially in difficult-to-treat populations, with a 20% or higher response rate seen as a strong benchmark for monotherapy.

• Noted that the INDUKINE platform has shown clinical validation, with ongoing efforts to apply its conditional activation technology to other biologics, including T-cell engagers.

• Differentiation of their approach centers on linker technology and fine-tuning conditional activation for stability and efficacy in tumor environments.

Clinical development and data updates

• WTX-124 monotherapy and combination expansion cohorts in melanoma, renal cell carcinoma, and cutaneous squamous cell carcinoma are enrolling, with full enrollment in melanoma expected by mid-year.

• Dose escalation is complete, with 18 mg selected for expansion; data packages will be discussed with regulatory agencies for potential registration pathways, including accelerated approval.

• Efficacy benchmarks include a 20%+ response rate and durable responses of at least four months for monotherapy, and higher rates and durability for combination therapy.

• Notable complete response in a refractory cutaneous squamous cell carcinoma patient, supporting the inclusion of this indication for potential accelerated registration.

Strategic direction and future plans

• Plans to leverage INDUKINE learnings for next-generation biologics, focusing on improved masking and linker design to enhance therapeutic index and tumor targeting.

• Ongoing studies with WTX-330 (IL-12) aim to optimize dosing strategies, including loading doses, to manage safety and maximize tumor microenvironment activation.

• Early data show distinct immune activation profiles for IL-12 versus IL-2, with upregulation of dendritic and antigen-presenting cell genes in patient biopsies.

• Further data on WTX-330 dosing strategies and indication exploration expected later in the year.